Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicated strong financial performance with an 83% revenue increase and improved gross margins. The strategic plan outlines international expansion and product development, while the Q&A section highlighted positive reception of the Swoop system and no impact from helium shortages. Despite a net loss, reduced R&D expenses and cash burn demonstrate financial discipline. The guidance aligns with growth initiatives, and the company's innovative approach and market potential suggest a positive stock price movement in the near term.
Key Financial Performance
Revenue $3.9 million, up 83% year-over-year. The increase was driven by the sale of 10 units compared to 6 units in the prior year period, with contributions across all 3 business verticals and a strong average selling price for the next-generation system.
Gross Margin 50.7%, up from 41.3% in the prior year period, representing approximately 940 basis points of gross margin expansion. This improvement was attributed to scaling and strong sales performance.
R&D Expenses $3.8 million, down 24% year-over-year from $5.0 million. The decrease was due to benefits realized from the reorganization completed in the first quarter of 2025 as the company transitioned to a commercial growth stage organization.
Sales, General and Administrative Expenses $6.7 million, flat compared to the first quarter of 2025. The company maintained a single U.S. sales team covering both hospital and office market opportunities, focusing on sales productivity and operating leverage.
Net Loss $8.6 million ($0.09 per share), compared to $9.4 million ($0.12 per share) in the first quarter of 2025. The improvement was due to reduced cash burn and spending discipline.
Net Cash Burn $8.8 million, down 13% year-over-year from $10.1 million. The improvement was attributed to spending discipline and improved operating leverage, despite the first quarter typically being the highest cash burn quarter due to annual one-time payments.
Cash and Cash Equivalents $40.8 million as of March 31, 2026. This includes a $15 million initial tranche under a long-term debt facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation Swoop system: Q1 marked the third full quarter of selling the next-generation Swoop system in the U.S. market, contributing to $3.9 million in revenue, an 83% year-over-year increase. The system has been implemented in hospitals, neurology offices, and international markets, with strong demand and positive clinical outcomes.
Advanced DWI Optive AI software: Launched at the 2026 International Stroke Conference, this software enhances stroke detection capabilities and is now implemented in most scanners across the installed base. It has received CE and UKCA marks, enabling future European market expansion.
Contrast PMR study: Enrollment is over 50% of the target, with three active study sites. The study aims to expand the Swoop system's indications to include contrast-enhanced imaging, with a potential FDA submission by the end of 2026.
International expansion: The first Swoop system is live in India at a leading KOL center in Delhi. CE and UKCA marks for the next-generation Swoop system and Optive AI software position the company for a European launch in Q3 2026.
Neurology office market: The Swoop system has been adopted in larger neurology offices, showing high diagnostic value for conditions like headaches, dementia, and multiple sclerosis. Positive patient feedback has been reported.
Revenue growth: Revenue for Q1 2026 was $3.9 million, up 83% year-over-year, driven by strong sales of the next-generation Swoop system.
Gross margin improvement: Gross margin reached 50.7%, up from 41.3% in Q1 2025, marking the third consecutive quarter above 50%.
Cash burn reduction: Net cash burn improved by 13% year-over-year, with a total of $8.8 million in Q1 2026.
IDN strategy: The company is focusing on multiunit and IDN opportunities to drive adoption of the Swoop system across hospitals, leveraging longer sales cycles for strategic expansion.
New care settings: Pilot activities are underway to evaluate the Swoop system's use in operating rooms, angio suites, and mobile units for community-based brain screening programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company faces risks related to obtaining regulatory approvals for its products, such as the FDA submission for the Contrast PMR study by the end of 2026. Delays or failures in obtaining these approvals could impact product launch timelines and market expansion.
Sales Cycle and Procurement Processes: The sales cycle for multiunit and IDN opportunities involves additional system-wide stakeholders and steps in procurement processes, which could delay revenue realization and adoption of the technology.
Cash Burn and Financial Sustainability: Despite improvements, the company continues to experience significant cash burn, with a projected total cash burn of $26 million to $28 million for 2026. This could pose challenges to financial sustainability if revenue growth or cost management does not meet expectations.
Market Expansion Challenges: The company is working to expand into international markets, including Europe and India. Delays in translations, documentation processes, or market reception could hinder the planned launch and growth in these regions.
Product Development and Innovation: The company plans to introduce a software upgrade by the end of 2026. Delays or technical challenges in product development could impact the clinical value and competitiveness of the Swoop system.
Economic and Competitive Pressures: The company operates in a competitive medical imaging market. Economic uncertainties or competitive pressures could impact pricing, market share, and overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects revenue between $20 million and $22 million for 2026, representing year-over-year growth at the midpoint of 55%. Revenue is expected to progressively strengthen through 2026, supported by a strong pipeline across three business verticals and the second half 2026 launch of the next-generation Swoop system in Europe.
Gross Margin Projections: Gross margin is expected to be in the range of 50% to 55% for the year 2026. Margins are anticipated to improve over the course of the year as sales volumes increase, with second-half gross margin percentages exceeding the first half. The company aims to sustain gross margins above 50% as growth initiatives are executed.
Cash Burn and Financial Management: Total cash burn for 2026 is expected to be in the range of $26 million to $28 million, representing a 10% year-over-year decline at the midpoint. The company anticipates a healthy cash runway extending into 2028, inclusive of the $15 million initial tranche of debt financing but exclusive of the additional $25 million of growth capital available under the facility.
Product Development and Launches: The company plans to introduce the next software upgrade for the Swoop system by the end of 2026, which will include additional improvements in image quality and clinical capabilities. The second half of 2026 will also see the launch of the next-generation Swoop system in Europe.
Clinical and Market Expansion: The company is evaluating new use cases for the Swoop system, including its use in operating rooms, angio suites, and mobile units for community-based brain screening programs. Additionally, the Contrast PMR study is progressing well, with enrollment over 50% of the target, and is expected to support a potential FDA submission by the end of 2026 to expand the Swoop system's intended use to include gadolinium-based contrast agents.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the typical decision criteria and timelines for IDNs and how many are at the standardization stage versus single-site pilots?
A:The IDN strategy is about 3 quarters deep. One IDN has moved from single-site to multiple sites, while others are in the initial placement stage. The process involves regional, divisional, or national approvals and procurement steps. After the first system's implementation and 2-3 months of data collection, additional sites within the IDN can begin procurement. This process takes about 8 weeks for data tabulation and sharing.
Q:What is included in the 2026 guidance, and how does it reflect the IDN initiatives?
A:The 2026 guidance includes contributions from hospitals (including IDNs), office businesses, and international growth. The second half of the year aligns better with budgetary cycles for IDN initiatives, given the clearance timing for the next-generation system.
Q:What is the profile of adopters in the office channel, and what signals are encouraging?
A:Larger offices, often grouped under NeuroNet, are the primary adopters due to higher patient volume and better return on investment. Smaller practices have lower volume and fewer resources, making the investment less attractive. Leads from the NeuroNet annual meeting in February translated into deals in Q1. The NEURO PMR data and Swoop system's utility resonate well with larger offices.
Q:Has the helium shortage in the U.S. impacted interactions with potential customers?
A:The system does not require helium, which is highlighted as a maintenance advantage. Customers have not directly raised concerns about helium shortages, but they appreciate the system's portability, lack of shielding requirements, and ability to plug into a standard outlet. These features are emphasized in discussions with hospitals and sites.
Q:What are the key economic factors highlighted when selling Swoop to new customers?
A:Key factors include reduced wait times for MRI in stroke patients (often 40-80 hours with high-field MRI), cost savings in the ICU (e.g., tubing, pumps, MRI-compatible supplies), and a 1-1.5 year ROI even with the MSRP of $590,000. Faster triage and reduced costs build a strong economic case.
Q:What is the expected impact of gadolinium contrast on adoption in hospital and office channels?
A:In hospitals, purchases are not being delayed for contrast availability, but contrast increases utility and reduces the need for multiple systems. In offices, contrast cases have higher reimbursement rates (30-50% higher), improving the economic calculation and making the investment more attractive.
Q:What is the timeline and requirements for expanding into new sites of care like the operating room and angio suite?
A:Interest from surgeons and interventionalists is growing for immediate post-procedure imaging. Publications and case series will be released this year. An advisory group is being formed to determine if software, coil modifications, or other adjustments are needed. A plan will be developed by year-end, with more details expected in the next couple of quarters.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity in the responses provided by management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI software
American
Brett
CE UKCA
Contrast PMR
DWI Optive
Europe
International Stroke
NEURO PMR
Neuroimaging
Optive AI
PMR study
Stroke Conference
Swoop system
UKCA mark
cash burn
contrast
debt
expansion
follow
generation Swoop
hospital
indication
loss
milestone
neurology office
site care
system use
tranche
value
vertical
HYPR Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call indicated strong financial performance with an 83% revenue increase and improved gross margins. The strategic plan outlines international expansion and product development, while the Q&A section highlighted positive reception of the Swoop system and no impact from helium shortages. Despite a net loss, reduced R&D expenses and cash burn demonstrate financial discipline. The guidance aligns with growth initiatives, and the company's innovative approach and market potential suggest a positive stock price movement in the near term.
AutoCanada Inc. (ACQ:CA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed significant challenges, including declining revenue and gross profit, operational disruptions, and inventory management issues. The Q&A highlighted ongoing pressures on used vehicle gross profit and the need for a strategic reset. Although there is potential for improvement in the long term, the immediate outlook remains negative due to these persistent challenges and market underperformance.
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings report shows strong financial performance with significant revenue and gross profit growth, reduced net loss, and improved cash burn. The optimistic guidance for 2026, strong pipeline, and increased pricing for Model 2 suggest positive future prospects. Despite some management avoidance in addressing specific deal sizes, the overall sentiment is positive, supported by the transition to broader clinical utility and strategic market expansion.
HYPR Slides
HYPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
